Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Selinexor - Karyopharm Therapeutics

Drug Profile

Selinexor - Karyopharm Therapeutics

Alternative Names: ATG-010; CRM1-nuclear-export-inhibitor; KPT-330; ONO 7705; XPOVIO

Latest Information Update: 09 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Karyopharm Therapeutics
  • Developer Catholic University of Louvain; Karyopharm Therapeutics; Ono Pharmaceutical; University of Texas Southwestern Medical Center
  • Class Acrylamides; Antineoplastics; Fluorinated hydrocarbons; Hydrazines; Pyrazines; Small molecules; Triazoles
  • Mechanism of Action Exportin-1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Multiple myeloma; Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple myeloma
  • Phase III Endometrial cancer; Liposarcoma
  • Phase II Acute myeloid leukaemia; Breast cancer; Diffuse large B cell lymphoma; Glioblastoma; Myelodysplastic syndromes; Myelofibrosis; Ovarian cancer; Peripheral T-cell lymphoma; Thymoma
  • Phase I/II Non-Hodgkin's lymphoma; Non-small cell lung cancer
  • Phase I B-cell lymphoma; Chronic lymphocytic leukaemia; Glioma; Malignant melanoma; Soft tissue sarcoma; Solid tumours
  • No development reported Cervical cancer; Colorectal cancer; Neuroendocrine tumours; Osteosarcoma
  • Discontinued Cutaneous T-cell lymphoma; Diabetic foot ulcer; Gastric cancer; Oesophageal cancer; Prostate cancer; Rectal cancer; Richter's syndrome; Small cell lung cancer; Squamous cell cancer

Most Recent Events

  • 06 Nov 2019 Karyopharm Therapeutics and National Cancer Institute completes a phase I trial in Chronic lymphocytic leukaemia and Non-hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in USA (PO) (NCT02303392)
  • 06 Nov 2019 Efficacy data from patients with Multiple myeloma (with disease progression following CAR-T therapy) released by Karyopharm Therapeutics
  • 02 Oct 2019 AmerisourceBergen and Karyopharm Therapeutics agree to co-promote selinexor in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top